MARKET

VSTM

VSTM

Verastem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.060
+0.070
+2.34%
Opening 10:22 09/23 EDT
OPEN
2.990
PREV CLOSE
2.990
HIGH
3.085
LOW
2.989
VOLUME
494.76K
TURNOVER
--
52 WEEK HIGH
4.935
52 WEEK LOW
1.140
MARKET CAP
553.12M
P/E (TTM)
-13.5819
1D
5D
1M
3M
1Y
5Y
BRIEF-Verastem Oncology Appoints Louis J. Denis As Chief Medical Officer
reuters.com · 1d ago
Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Louis J. Denis, M.D., as Chief Medical Officer. Dr. Denis brings more than 25 years of clinical d...
Business Wire · 1d ago
Why Verastem Shares Are Trading Higher Today
Verastem Inc (NASDAQ: VSTM) is trading higher Monday after the company announced updated investigator-sponsored Phase 1/2 FRAME study data of VS-6766 with defactinib in low-grade serous ovarian cancer showing "encouraging response rates and progression-fre...
Benzinga · 2d ago
SDC, EDSA and APRE among pre market gainers
ZIVO Bioscience (NASDAQ:ZIVO) +175%. Verastem (NASDAQ:VSTM) +22% Oncology's VS-6766 + defactinib combo shows promising action in ovarian cancer study Edesa Biotech (NASDAQ:EDSA) +33% announces positive phase 2 data of its monoclonal antibody in
Seekingalpha · 3d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 3d ago
Verastem Oncology And Amgen Partner To Evaluate VS-6766 In Combination With LUMAKRASTM In Patients With KRAS G12C-Mutant Non-Small Cell Lung Cancer
Clinical Collaboration Will Assess Safety and Efficacy of More Complete Vertical Blockade Along RAS Pathway Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients
Benzinga · 3d ago
24 Stocks Moving in Monday's Pre-Market Session
Gainers Verastem, Inc. (NASDAQ: VSTM) rose 30.8% to $3.61 in pre-market trading after the company announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 1/2 FRAME study.
Benzinga · 3d ago
Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRAS(TM) (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766, Verastem Oncology's invest...
Business Wire · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VSTM. Analyze the recent business situations of Verastem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VSTM stock price target is 6.25 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 217
Institutional Holdings: 118.34M
% Owned: 65.47%
Shares Outstanding: 180.76M
TypeInstitutionsShares
Increased
39
15.57M
New
33
8.48M
Decreased
51
7.74M
Sold Out
15
814.56K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.19%
Key Executives
President/Chief Operating Officer
Daniel Paterson
Chief Executive Officer/Director
Brian Stuglik
Chief Financial Officer
Robert Gagnon
Lead Director/Independent Director
Michael Kauffman
Director
Paul Bunn
Director
Lesley Solomon
Independent Director
Timothy Barberich
Independent Director
Gina Consylman
Independent Director
John Johnson
Independent Director
Eric Rowinsky
No Data
  • All
  • Financials
  • Insiders
More
About VSTM
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.

Webull offers kinds of Verastem Inc stock information, including NASDAQ:VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.